FRE Firebrick Pharma Limited
—Mkt Cap: —P/E: —1d ago
Firebrick Pharma Limited develops and commercializes povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal and throat spray PVP-I products for the …
Industry Peers
Drug Manufacturers - GeneralKey Statistics
Company
Market Cap—
Enterprise Value5.00M USD
Revenue (TTM)93.72K USD
Gross Profit72.44K USD
Net Income (TTM)-1.82M USD
Revenue/Share0.0010 AUD
Last Price—
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees—
CountryAU
SectorHealthcare
IndustryDrug Manufacturers - General
ISINAU0000197352
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-2.44
EV/Revenue53.35
P/S67.77
P/B5.33
EPS (TTM)-0.01
EPS (Forward)—
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin35.72%
Oper. Margin-4041.53%
EBITDA Margin0.00%
Profit Margin-897.83%
ROE-169.27%
ROA-144.14%
Growth
Revenue Growth-86.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.80M USD
CapEx (TTM)57.35K USD
FCF Margin-1082.87%
FCF Yield—
Net Debt-913.24K USD
Net Debt/EBITDA0.45
Balance Sheet
Debt/Equity—
Current Ratio3.85
Quick Ratio2.84
Book Value/Sh0.0060 AUD
Cash/Share0.0050 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.287.20M
Float147.07M
Insiders45.12%
Institutions0.00%
Technical
SMA 500.0293 AUD
SMA 2000.0444 AUD
Beta0.90
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)160.72K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—